Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Wang, Huafeng  [Clear All Filters]
2024
Dong H, He X, Zhang L, Chen W, Lin Y-C, Liu S-B, Wang H, Nguyen LXuan Truon, Li M, Zhu Y, et al. Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity. Nat Cancer. 2024.
2023
Zhang B, Zhao D, Chen F, Frankhouser D, Wang H, Pathak KV, Dong L, Torres A, Garcia-Mansfield K, Zhang Y, et al. Acquired miR-142 deficit in leukemic stem cells suffices to drive chronic myeloid leukemia into blast crisis. Nat Commun. 2023;14(1):5325.
Yao Y, Lin X, Wang C, Gu Y, Jin J, Zhu Y, Wang H. Identification of a novel NPM1 mutation in acute myeloid leukemia. Exp Hematol Oncol. 2023;12(1):87.
2022
Wang H, Mao L, Yang M, Qian P, Lu H, Tong H, Xie W, Zhou D, Huang X, Wang Y, et al. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022.
2020
Huang J, Huang S, Ma Z, Lin X, Li X, Huang X, Wang J, Ye W, Li Y, He D, et al. Ibrutinib Suppresses Early Megakaryopoiesis but Enhances Proplatelet Formation. Thromb Haemost. 2020.
2018
Hu M, Wang H, Wang L, Yang M, Lou Y, Jin J. Outcome of adult T-lymphoblastic lymphoma depends on ALL-type chemotherapy, prognostic factors, and performance of allogeneic hematopoietic stem cell transplantation. Medicine (Baltimore). 2018;97(28):e11374.